Merck Stock's Ticking Keytruda Time Bomb

Merck's reliance on Keytruda, which accounts for 46% of total revenue and drove substantial growth with a 72% increase from 2021 to $29 billion last year, poses a significant risk as its U.S. market exclusivity ends in 2028, potentially leading to a sharp decline in sales due to biosimilar competition, similar to the sales erosion experienced by AbbVie's Humira and Roche's Herceptin; this impending patent cliff and a recent decline in Gardasil sales have already contributed to a 40% drop in MRK stock, highlighting the need for investors to diversify and balance risk.

Analysis

Merck's financial performance is heavily reliant on its oncology drug, Keytruda, which accounted for 46% of total revenues and saw sales surge 72% from $17 billion in 2021 to $29 billion in the last reported year, driving the company's double-digit average revenue growth over the past three years. However, this concentration presents a significant future risk, as Keytruda's U.S. market exclusivity is set to expire in 2028, exposing it to inevitable biosimilar competition. Historical precedents, such as AbbVie's Humira, which lost nearly 60% of its sales from a peak of $21 billion in 2022 to under $9 billion last year post-biosimilar entry, and Roche's Herceptin, whose sales declined from $7 billion in 2018 to $3.7 billion in 2020 after U.S. exclusivity loss in 2019, illustrate the potential magnitude of revenue erosion. While Keytruda's sales are projected to peak around $36 billion by 2028, they could subsequently fall to $20 billion or even below $15 billion within four to five years. This impending patent cliff, coupled with slowing sales of Gardasil, Merck's second best-selling drug, due to reduced demand in China, has contributed to a 40% decline in MRK stock over the past twelve months, reflecting investor anticipation of these challenges. Consequently, Merck faces the critical task of developing or acquiring new revenue streams within the next three years to offset the anticipated decline from Keytruda, failing which it may experience significantly slower growth or even falling sales, likely impacting its valuation.

Key Decisions for Investors

• Investors should critically assess Merck's significant revenue concentration in Keytruda and the well-defined timeline of its patent expiration in 2028, factoring in the historical sharp sales declines seen with other blockbuster drugs post-biosimilar entry.
• Monitor Merck's strategic initiatives, including acquisitions, licensing deals, and R&D pipeline progress, for evidence of successful revenue diversification ahead of the Keytruda patent cliff.
• Given the anticipated pressure on future revenues and valuation, particularly around 2028, and the recent stock underperformance, investors should consider the heightened risk profile and the importance of portfolio diversification to mitigate exposure to this single-product dependency.